Drug Search Results
More Filters [+]

Semaxanib

Alternative Names: semaxanib, su5416
Latest Update: 2023-09-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFR2 Inhibitor,AhR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Semaxanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Colorectal Cancer

Phase 2: Gastrointestinal Stromal Tumors|Astrocytoma|Glioma|Colorectal Cancer|Melanoma|Plasmacytoma|Head and Neck Cancer|Multiple Myeloma|Squamous Cell Carcinoma|Brain Stem Cancer|Sarcoma|Renal Cell Carcinoma|Skin Cancer|Kidney Cancer|Prostate Cancer|Acute Myelomonocytic Leukemia|Cervical Cancer|Anemia, Refractory, with Excess of Blasts|Acute Monocytic Leukemia|Adenocarcinoma|Anemia, Aplastic|Uterine Cancer|Mesothelioma|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|HIV Infections|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Preleukemia|Sarcoma, Kaposi

Phase 1: Oncology Solid Tumor Unspecified|Sarcoma, Kaposi|Brain Stem Cancer|Head and Neck Cancer|Prostate Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Vascular Cancer|Ovarian Cancer|Inflammatory Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SUGEN-SU5416.031

P3

Completed

Colorectal Cancer

2007-09-01

U01CA062505

P2

Completed

Renal Cell Carcinoma|Kidney Cancer

2007-02-01

NCI-2012-02351

P2

Completed

Mesothelioma

2007-02-01

NCI-2012-02345

P2

Terminated

Colorectal Cancer

2007-02-01

Recent News Events